Literature DB >> 18849073

Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell?

Piotr Tabaczewski1, Sushani Nadesan, Seah H Lim.   

Abstract

Essential thrombocythemia (ET) co-existing with chronic lymphocytic leukemia (CLL) is extremely rare. We report two cases of ET with Jak 2 V617F in Zap-70+ CLL. ET is a myeloproliferative stem cell disease. Zap-70 expression in CLL correlates with non-mutated immunoglobulin genes. The occurrence of a less mature CLL in patients with a pluripotential stem cell disease raises the possibility that an initial "trigger hit" occurred in a pre-Jak 2 common early progenitor in these patients. Subsequent additional molecular events accumulated independently following myeloid and lymphoid differentiation, leading to the development of two diseases of likely identical origin but different lineages.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18849073      PMCID： PMC2695994          DOI： 10.1016/j.leukres.2008.09.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  10 in total

1.  Coexistence of essential thrombocythemia and chronic lymphocytic leukemia.

Authors:  N Y Gabrail; T W Martin
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

2.  Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.

Authors:  Laurent Henry; Serge Carillo; Eric Jourdan; Anne Arnaud; Sophie Brun; Thierry Lavabre-Bertrand
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

3.  Chronic lymphocytic leukaemia in a patient with essential thrombocythaemia.

Authors:  N Bizzaro
Journal:  Clin Lab Haematol       Date:  1998-12

4.  [Simultaneous presentation of chronic lymphocytic leukosis and essential thrombocythemia].

Authors:  F Marcos Sánchez; F Juárez Ucelay; C Lobato de Blas; M L Llanos del Ama; A Durán Pérez-Navarro
Journal:  An Med Interna       Date:  1995-11

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Authors:  Adrian Wiestner; Andreas Rosenwald; Todd S Barry; George Wright; R Eric Davis; Sarah E Henrickson; Hong Zhao; Rachel E Ibbotson; Jenny A Orchard; Zadie Davis; Maryalice Stetler-Stevenson; Mark Raffeld; Diane C Arthur; Gerald E Marti; Wyndham H Wilson; Terry J Hamblin; David G Oscier; Louis M Staudt
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

Review 7.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

8.  Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia.

Authors:  W H Raskind; R Jacobson; S Murphy; J W Adamson; P J Fialkow
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

Review 9.  Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.

Authors:  Tadeusz Robak; Halina Urbańska-Ryś; Joanna Góra-Tybor; Ewa Wawrzyniak; Anna Korycka; Jacek Bartkowiak; Radzisław Kordek; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2003-08

10.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Authors:  Peter J Campbell; E Joanna Baxter; Philip A Beer; Linda M Scott; Anthony J Bench; Brian J P Huntly; Wendy N Erber; Rajko Kusec; Thomas Stauffer Larsen; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Martin Griesshammer; John T Reilly; Betty Y Cheung; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113
  10 in total
  10 in total

1.  Concomitant Myeloproliferative and Lymphoid Neoplasms in Two Patients Positive for JAK2 V617F Mutation. Case Report and Literature Review.

Authors:  Adrian P Trifa; Andrei Cucuianu; Radu A Popp; Mariana Paţiu; Cristina Selicean; Mariela S Militaru; Ioan V Pop
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-14       Impact factor: 0.900

2.  Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature.

Authors:  Filipa Mousinho; Paula Sousa E Santos; Ana P Azevedo; José Manuel Pereira; Raquel Lemos; Sónia Matos; João Faro Viana; Fernando Lima
Journal:  Mol Clin Oncol       Date:  2018-07-19

3.  MYBPC1 computational phosphoprotein network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients.

Authors:  Lin Wang; Juxiang Huang; Minghu Jiang; Lingjun Sun
Journal:  Cell Mol Neurobiol       Date:  2011-03       Impact factor: 5.046

4.  Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization.

Authors:  Hyunjung Kim; Woori Jang; Soyoung Shin; Joonhong Park; Myungshin Kim; Yonggoo Kim; Kyungja Han; Gun Dong Lee; Heusung Won; Young Jun Yang
Journal:  Int J Hematol       Date:  2014-12-10       Impact factor: 2.490

5.  Coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm.

Authors:  Patrycja Zielinska; Miroslaw Markiewicz; Monika Dzierzak-Mietla; Anna Koclega; Grzegorz Helbig; Slawomira Kyrcz-Krzemien
Journal:  Case Rep Oncol Med       Date:  2014-09-02

6.  Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia.

Authors:  Guido D'Angelo; Anna Maria Hotz; Fabrizio Ciambelli; Sergio Pauli
Journal:  Blood Res       Date:  2014-06-25

7.  Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance.

Authors:  Saeid Shahrabi; Ali Ehsanpour; Somayyeh Heidary; Mohammad Shahjahani; Masumeh Maleki Behzad
Journal:  Oncol Rev       Date:  2018-10-02

8.  JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases.

Authors:  Yi-Ning Yang; You-Wen Qin; Chun Wang
Journal:  Oncol Lett       Date:  2014-05-22       Impact factor: 2.967

9.  Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience.

Authors:  Anthi Bouchla; Thomas Thomopoulos; Sotirios Papageorgiou; Panagiotis Tsirigotis; Efthymia Bazani; Konstantinos Gkirkas; Diamantina Vasilatou; Eirini Glezou; Georgia Stavroulaki; Konstantinos Gkontopoulos; George Dimitriadis; Vasiliki Pappa
Journal:  Adv Hematol       Date:  2019-11-03

10.  Lymphoproliferative and Subsequent Myeloproliferative Disorder - A One Way Street?

Authors:  Pawina Subedi; Yugandhara Kate; Masood Pasha Syed; A Daniyal Siddiqui
Journal:  Balkan Med J       Date:  2021-05       Impact factor: 2.021
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.